Yes, some T Cell Engagers have received regulatory approval. For instance, Blinatumomab (Blincyto) is a bispecific T cell engager (BiTE) approved for the treatment of certain types of B-cell acute lymphoblastic leukemia (ALL). This approval has paved the way for the development and approval of other T Cell Engagers targeting different cancer types.
